Journal Watch · The New England Journal of Medicine · 2026

Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.

(Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

Vedantham S, Kahn SR, Marston WA et al.The New England Journal of Medicine4 min readPharma relevance 75/100

DOI: 10.1056/nejmoa2519001PMID: 41972998Study type: randomised / controlled clinical trial

TL;DR

(Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

Key findings

  • Through 6 months, bleeding was more common in the endovascular-therapy group than in the no-endovascular-therapy group (in 11.6% vs.
  • 3.6% of the patients; P = 0.03).<h4>Conclusions</h4>Among patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction, endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period but with a higher risk of bleeding.
  • (Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

Numbers at a glance (from the abstract)

11.6%3.6%P = 0.001P<0.001P = 0.03

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Key secondary outcomes included venous disease-specific and overall quality of life.<h4>Results</h4>At 6 months, the severity of post-thrombotic syndrome was lower in the endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD] VCSS, 8.1±5.1 vs. 10.0±4.9; adjusted difference, -2.0; P = 0.001). Venous disease-specific quality of life as assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire was better in the endovascular-therapy group than in the no-endovascular-therapy group at 6 months (adjusted difference, 14.5 points; P<0.001), as was overall quality of life as assessed with the Medical Outcomes Study 36-Item Short-Form Health Status Survey physical component summary score (adjusted difference, 6.1 points; P<0.001); scores on both tools range from 0 to 100.

Full abstract (original)

Background: <h4>Background</h4>Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients' activity and quality of life. Endovascular therapy can eliminate chronic venous obstruction and is hypothesized to reduce the severity of post-thrombotic syndrome.<h4>Methods</h4>We randomly assigned 225 patients with moderate or severe post-thrombotic syndrome and imaging-confirmed iliac-vein obstruction to receive endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) plus standard post-thrombotic syndrome care or standard post-thrombotic syndrome care alone. The severity of post-thrombotic syndrome at 6 months (the primary outcome) was assessed with the validated Venous Clinical Severity Score (VCSS) tool (scores range from 0 to 30, with higher scores indicating more severe post-thrombotic syndrome) by evaluators who were unaware of the group assignments.

What they did: Key secondary outcomes included venous disease-specific and overall quality of life.<h4>Results</h4>At 6 months, the severity of post-thrombotic syndrome was lower in the endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD] VCSS, 8.1±5.1 vs. 10.0±4.9; adjusted difference, -2.0; P = 0.001). Venous disease-specific quality of life as assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire was better in the endovascular-therapy group than in the no-endovascular-therapy group at 6 months (adjusted difference, 14.5 points; P<0.001), as was overall quality of life as assessed with the Medical Outcomes Study 36-Item Short-Form Health Status Survey physical component summary score (adjusted difference, 6.1 points; P<0.001); scores on both tools range from 0 to 100.

Results & conclusions: Through 6 months, bleeding was more common in the endovascular-therapy group than in the no-endovascular-therapy group (in 11.6% vs. 3.6% of the patients; P = 0.03).<h4>Conclusions</h4>Among patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction, endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period but with a higher risk of bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

Abstract © the authors / The New England Journal of Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1056/nejmoa2519001 · PubMed 41972998.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking The New England Journal of Medicine for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this The New England Journal of Medicine study find?

(Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

What type of study is this?

It is a randomised / controlled clinical trial, published in The New England Journal of Medicine in 2026. Key secondary outcomes included venous disease-specific and overall quality of life.<h4>Results</h4>At 6 months, the severity of post-thrombotic syndrome was lower in the endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD] VCSS, 8.1±5.1 vs.

Where can I read the original paper?

The original is at the publisher via DOI 10.1056/nejmoa2519001. PubMed ID: 41972998. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Vedantham S, Kahn SR, Marston WA et al.. Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.. The New England Journal of Medicine (2026). DOI: 10.1056/nejmoa2519001.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/endovascular-therapy-for-post-thrombotic-syndrome-a-randomized-trial-519001/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides